Prognostic significance of ALCAM (CD166/MEMD) expression in cutaneous melanoma patients

Diagnostic Pathology

Table 3 Correlations between clinicopathological and histopathological characteristics and ALCAM expression parameters in primary tumors and nodal metastases

	ALCAM expression – primary tumor			ALCAM expression – nodal metastasis
Clinicopathological parameters	%^a	Int^b	IRS^c	%^a	Int^b	IRS^c
pT^ad	0.0001	0.245	0.016	0.257	0.977	0.659
pN^e	0.211	0.228	0.805	0.439	0.952	0.870
Distant metastases^e	0.145	0.886	0.152	0.257	0.596	0.749
Recurrence^e	0.161	0.082	0.705	0.705	0.906	0.669
Age^d	0.368	0.555	0.303	0.467	0.866	0.793
Gender^e	0.452	0.596	0.699	0.166	0.724	0.699
Primary tumor location^f	0.412	0.470	0.586	0.779	0.864	0.992
Histopathological parameters	%	Int	IRS	%	Int	IRS
Breslow thickness^d	0.003	0.342	0.008	0.340	0.865	0.744
Clark level^d	0.026	0.912	0.001	0.032	0.598	0.400
Growth phase^e	0.422	0.714	0.568	100 % vertical growth phase
Histologic type^f	0.523	0.082	0.749	0.529	0.906	0.709
Mitotic rate^d	0.050	0.163	0.536	0.834	0.825	0.976
Ulceration^e	0.035	0.795	0.086	0.564	0.840	0.625
Lymphangioinvasion^e	0.523	0.379	0.480	0.439	0.147	0.274
Microsatellitosis^e	0.249	0.381	0.616	0.439	0.717	0.444
Tumor-infiltrating lymphocytes (TILs)^f	0.010	0.389	0.451	0.967	0.359	0.549
Tumor regression^e	0.761	0.364	0.771	100 % without regression

^aPercentage of ALCAM-positive melanoma cells (0–4 points)
^bIntenisty of immunohistochemical reaction (0–3 points)
^cImmunoReactive Score (product of the scores for the percentage of positive cells and intensity of reaction (0–12 points)
^d P value of Spearman rank correlation
^e P value of Mann-Whitney’s U test
^f P value of Kruskal-Wallis test
Statistically significant results (P < 0.05) are in bold font

ISSN: 1746-1596